New drug cocktail targets Hard-to-Treat colon cancer mutation
NCT ID NCT05722327
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether adding a new targeted drug called adagrasib to two existing cancer drugs (cetuximab and irinotecan) is safe and tolerable for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The study will enroll 24 patients whose cancer has spread or cannot be removed and who have already tried at least two prior treatments. The main goal is to find the best dose and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adagrasib (MRTX849), cetuximab, irinotecan
- What this could lead to
- If it works, this could point toward a new treatment option for people with a specific genetic type of colorectal cancer that has not responded to prior therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, focused on safety and dosing. It is too small and early to know if the combination will be effective or widely usable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?